A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer

A minority of patients with gastroesophageal adenocarcinoma derive benefit from immune-checkpoint inhibition (ICI). In a large-cohort phase III study, the nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) arm (which was based on promising preliminary data from CheckMate 032) was closed owing to unaccept...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Clinical oncology 2019-01, Vol.16 (1), p.9-10
Hauptverfasser:	Harada, Kazuto, Abdelhakeem, Ahmed A. F., Ajani, Jaffer A.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/154/1438 631/67/1059/2325 692/4028/67/1504/1477 692/4028/67/1504/1829 Adenocarcinoma Apoptosis Biological markers Cancer Cancer metastasis Cancer patients Cancer prevention Care and treatment Cell death Development and progression DNA Enzyme inhibitors Esophageal cancer Gene expression Genetic aspects Health aspects Humans Immune checkpoint inhibitors Immunotherapy Ipilimumab Medicine Medicine & Public Health Monoclonal antibodies Morbidity Mortality Neoplasms Neoplasms, Second Primary News & Views news-and-views Nivolumab Oncology PD-1 protein PD-L1 protein Phosphotransferases Surgery Targeted cancer therapy Tumors Universities and colleges
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A minority of patients with gastroesophageal adenocarcinoma derive benefit from immune-checkpoint inhibition (ICI). In a large-cohort phase III study, the nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) arm (which was based on promising preliminary data from CheckMate 032) was closed owing to unacceptably high levels of mortality and morbidity. Our quest for better biomarkers than programmed cell death 1 ligand 1 (PD-L1) and safer dual ICI strategies must continue.
ISSN:	1759-4774 1759-4782
DOI:	10.1038/s41571-018-0108-x